Combined treatment with SLC-391 and venetoclax decreases the leukemia burden and prolongs the survival of leukemic mice. (A) Schematic diagram of the experimental design. (B) Noninvasive in vivo bioluminescence imaging of NSG mice 1 week after discontinuation of oral gavage treatments with vehicle, 50 mg/kg SLC-391 (SLC; n = 3), 50 mg/kg venetoclax (VEN; n = 3), or both (SLC+VEN; n = 4). Three representative mice are shown. (C) Bioluminescent imaging intensity was measured in each animal from the ROIs shown in panel B and is presented as total photon counts per second. The P values were calculated using 1-way ANOVA with Tukey's post hoc correction for multiple comparisons. (D) Representative spleen appearance and weights of mice euthanized after 3 weeks of oral gavage treatments. (E) FACS analysis of GFP⁺ cells in BM, PB, and spleen of the same euthanized mice. (F) Overall survival of mice from each treatment group (n = 4-6 mice per group). Median survival for each treatment group is indicated in days in parentheses. The P values were calculated using a log-rank (Mantel-Cox) test. (G) Hematoxylin and eosin staining and CD45 staining of representative spleen tissue of mice from each treatment group (n = 1 mouse per treatment group) after 3 weeks of oral gavage treatment. Scale bars, 50μm. ctrl, control; FSC, forward scatter; IVIS, in vivo imaging system.